logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 11 of 11 Items
Showing 1 - 11 of 11 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|
Letter

Linezolid resistance in patients with drug-resistant TB

Vengurlekar D, Walker C, Mahajan R, Dalal A, Chavan VV,  et al.
2023-07-01 • International Journal of Tuberculosis and Lung Disease
2023-07-01 • International Journal of Tuberculosis and Lung Disease
Conference Material
|
Slide Presentation

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
Bedaquiline (BDQ) and linezolid (LZD) are Group A drugs and form part of shorter and longer BDQ-based regimens under India’s National Tuberculosis (TB) Programme. A syst...
Journal Article
|
Research

Clinical utility of target-based next-generation sequencing for drug-resistant TB

Mansoor H, Hirani N, Chavan VV, Das M, Sharma J,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid re...
Journal Article
|
Research

Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India

Dhakulkar S, Das M, Sutar N, Oswal V, Shah D,  et al.
2021-02-18 • PLOS One
2021-02-18 • PLOS One
BACKGROUND
Childhood and adolescent drug-resistant TB (DR-TB) is one of the neglected infectious diseases. Limited evidence exists around programmatic outcomes of children and adoles...
Journal Article
|
Research

Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges

Chavan VV, Dalal A, Nagaraja SB, Thekkur P, Mansoor H,  et al.
2020-06-16 • PLOS One
2020-06-16 • PLOS One
Background
Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is...
Conference Material
|
Poster

Treatment outcomes of bedaquiline-exposed tuberculosis patients treated with a regimen containing bedaquiline and delamanid: findings from MSF clinic, Mumbai, India

Mongia H, Mansoor H, Mamnoon F, Silsarma A, Davuluri P,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Slide Presentation

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
Conference Material
|
Video

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-06-07 • MSF Scientific Days International 2022
2022-06-07 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Abstract

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
In countries with a high tuberculosis (TB) burden, poor access to drug susceptibility testing is a major bottleneck in diagnosing drug-resistant (DR) TB. India is estima...